Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Comparison of fluorescence in situ hybridization, NMP22 bladderchek, and urinary liquid-based cytology in the detection of bladder urothelial carcinoma.

Li HX, Wang MR, Zhao H, Cao J, Li CL, Pan QJ.

Diagn Cytopathol. 2013 Oct;41(10):852-7. doi: 10.1002/dc.22969. Epub 2013 Feb 27.

PMID:
23444210
2.

Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.

Moonen PM, Kiemeney LA, Witjes JA.

Eur Urol. 2005 Dec;48(6):951-6; discussion 956. Epub 2005 Sep 26.

PMID:
16257108
3.

Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.

Kehinde EO, Al-Mulla F, Kapila K, Anim JT.

Scand J Urol Nephrol. 2011 Mar;45(2):113-21. doi: 10.3109/00365599.2010.533694. Epub 2010 Nov 22.

PMID:
21091091
4.

Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer.

Yoo JH, Suh B, Park TS, Shin MG, Choi YD, Lee CH, Choi JR.

Cancer Genet Cytogenet. 2010 Apr 15;198(2):107-17. doi: 10.1016/j.cancergencyto.2009.12.017.

PMID:
20362225
5.

Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.

Tritschler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, Stief CG, Zaak D.

Eur Urol. 2007 Feb;51(2):403-7; discussion 407-8. Epub 2006 Aug 15.

PMID:
16939699
6.

Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.

Kumar A, Kumar R, Gupta NP.

Jpn J Clin Oncol. 2006 Mar;36(3):172-5. Epub 2006 Mar 6.

PMID:
16520358
7.

Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.

Todenhöfer T, Hennenlotter J, Esser M, Mohrhardt S, Tews V, Aufderklamm S, Gakis G, Kuehs U, Stenzl A, Schwentner C.

Cancer Cytopathol. 2013 May;121(5):252-60. doi: 10.1002/cncy.21247. Epub 2012 Nov 21.

8.

Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.

Arora VK, Sarungbam J, Bhatia A, Singh N, Agrawal V, Aggarwal S.

Diagn Cytopathol. 2010 Nov;38(11):788-90. doi: 10.1002/dc.21286.

PMID:
20014314
9.

[Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma].

Li M, Li HX, Guo HQ, Zhao H, Zhao LL, Ma JH, Li CL, Cao J, Pan QJ.

Zhonghua Zhong Liu Za Zhi. 2012 Sep;34(9):669-73. doi: 10.3760/cma.j.issn.0253-3766.2012.09.006. Chinese.

PMID:
23159079
10.

[Value of fluorescence in situ hybridization of urine exfoliative cells in diagnosis of urinary bladder neoplasms].

Chen N, Gong J, Zeng H, Wei Q, Zhu YC, Chen M, Zhou Q.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 Jan;42(1):109-13. Chinese.

PMID:
21355314
11.

Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer.

Marín-Aguilera M, Mengual L, Ribal MJ, Burset M, Arce Y, Ars E, Oliver A, Villavicencio H, Algaba F, Alcaraz A.

Cancer Genet Cytogenet. 2007 Mar;173(2):131-5.

PMID:
17321328
13.
14.

[The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].

Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E.

Arch Esp Urol. 2008 Apr;61(3):377-84. Spanish.

PMID:
18581675
15.

Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.

Al-Maghrebi M, Kehinde EO, Kapila K, Anim JT.

Med Princ Pract. 2012;21(3):295-7. doi: 10.1159/000334811. Epub 2012 Jan 11.

16.

ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.

Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ.

Anal Quant Cytol Histol. 2010 Feb;32(1):45-52.

PMID:
20701087
18.

Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.

Veeramachaneni R, Nordberg ML, Shi R, Herrera GA, Turbat-Herrera EA.

Diagn Cytopathol. 2003 Jun;28(6):301-7.

PMID:
12768634
20.

Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.

Smrkolj T, Mihelič M, Sedlar A, Sterle I, Osredkar J, Sedmak B.

Clin Chem Lab Med. 2011 Feb;49(2):311-6. doi: 10.1515/CCLM.2011.038. Epub 2010 Dec 1.

PMID:
21118051

Supplemental Content

Support Center